Doripenem versus Pseudomonas aeruginosa in ... | 合法藥品大搜索

據估計，醫療院所內金黃色葡萄球菌(Staphylococcus aureus)對methicillin的抗藥性已經高達60%，腸球菌(Enterococcus)與綠膿桿菌(Pseudomonas aeruginosa)​ ... Read More

由 M Castanheira 著作 · 2009 · 被引用 102 次 — Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Read More

由 S Mushtaq 著作 · 2004 · 被引用 227 次 — Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i) Pseudomonas​ ... Read More

由 C Bretonnière 著作 · 2010 · 被引用 17 次 — Conclusions: In this model of P. aeruginosa pneumonia, doripenem had an efficacy equivalent to that of meropenem and imipenem at a high ... Read More

由 CE Luyt 著作 · 2014 · 被引用 59 次 — Only limited data exist on Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) treated with imipenem, meropenem, or doripenem ... Read More

由 E Riera 著作 · 2011 · 被引用 173 次 — Mutation-driven resistance was studied in 60 non-MBL producers according to the doripenem MICs (15 isolates from each of four MIC groups: ≤ 1, 2-4, 8-16 and ... Read More

由 NS Ly 著作 · 2015 · 被引用 62 次 — Our findings provide insight into optimal antibiotic treatment and may serve as a framework for new drug combinations and combination ... Read More

由 S Mushtaq 著作 · 2004 · 被引用 228 次 — Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential. Read More

由 A Negi 著作 · 2017 · 被引用 4 次 — Pseudomonas aeruginosa is one of the leading pathogen causing healthcare-​associated infections, particularly in immunocompromised and critically ill patients. Read More

由 S Mushtaq 著作 · 2004 · 被引用 228 次 — Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance ... Read More